Get the Stockscreener App
18.52
0.11%
-0.02
After Hours:
18.52
Pharvaris Nv stock is traded at $18.52, with a volume of 53,009.
It is down -0.11% in the last 24 hours and up +2.89% over the past month.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .
See More
Previous Close:
$18.54
Open:
$18.52
24h Volume:
53,009
Relative Volume:
0.62
Market Cap:
$994.28M
Revenue:
-
Net Income/Loss:
$-123.41M
P/E Ratio:
-8.6623
EPS:
-2.138
Net Cash Flow:
$-106.93M
1W Performance:
-2.94%
1M Performance:
+2.89%
6M Performance:
-19.86%
1Y Performance:
-11.26%
1-Day Range:
$18.23
$18.70
1-Week Range:
$18.10
$19.40
52-Week Range:
$15.00
$33.00
Pharvaris Nv Stock (PHVS) Company Profile
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Novo Holdings A S Has $32.43 Million Stock Position in Pharvaris (NASDAQ:PHVS) - MarketBeat
Pharvaris CBO Resigns, Team Absorbs Duties - TipRanks
(PHVS) Technical Data - Stock Traders Daily
Hereditary Angioedema Therapeutics Global Market Report Explores 2024: Size Forecast and Growth Prospects 2033 - WhaTech
Pharvaris (NASDAQ:PHVS) Shares Gap Down to $21.09 - MarketBeat
Jones Trading Initiates Coverage of Pharvaris N.V. (PHVS) with Buy Recommendation - MSN
Paradise, NV – Injuries Reported in Vehicle Accident on I-215 W near Las Vegas Blvd Onramp - Local Accident Reports
Las Vegas, NV – Accident on I-215 E near Windmill Ln Results in Injuries - Local Accident Reports
North Las Vegas Man Charged in Fatal Hit-and-Run After Allegedly Fleeing Accident Scene - Hoodline
Paradise, NV – Vehicle Accident at I-215 E and Las Vegas Blvd - Local Accident Reports
Las Vegas, NV – Vehicle Accident at CC215 S and W Sunset Rd Causes Injuries - Local Accident Reports
Highway reopens outside Las Vegas after crash, fire in semi hauling lithium batteries - KRNV
Highway reopens outside Las Vegas after crash, fire in semi hauling lithium batteries - FoxReno.com
Road closures persist after trucks carrying wood and batteries collide - News3LV
Appeal over identifying invasive hornets in Jersey - BBC.com
Hwy 95 closes in Nye County after crash involving truck carrying lithium batteries - Audacy
1 person transported to hospital after Henderson crash involving bicyclist - Fox 5 Las Vegas
1 hospitalized in Henderson crash involving bicyclistKLAS - KLAS - 8 News Now
Oregon man dies northwest of Las Vegas Valley, state police say - Fox 5 Las Vegas
1 person taken to hospital after crash involving car, bicyclist in Henderson - News3LV
Rep. Steven Horsford releases updated campaign ad after LVPPA concerns - KTNV 13 Action News Las Vegas
Silver Springs man killed in crash on U.S. 50A & 6th Street in Fernley - KTVN
Las Vegas, NV – Collision at CC215 S & W Flamingo Rd Results in Injuries - Local Accident Reports
Pharvaris (NASDAQ:PHVS) Shares Gap Up After Analyst Upgrade - MarketBeat
Pharvaris stock outlook strengthened with price target increase, Outperform rating reiterated by Oppenheimer - Investing.com UK
(PHVS) Technical Pivots with Risk Controls - Stock Traders Daily
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and ... - The Bakersfield Californian
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant - StockTitan
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024 - StockTitan
Pharvaris Presents Data at the Bradykinin Symposium 2024 - StockTitan
Pharvaris to Present at SVB Securities Global Biopharma Conference - Yahoo Finance UK
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium - Yahoo Finance UK
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium - StockTitan
Pharvaris (NASDAQ:PHVS) Shares Gap Down to $19.08 - MarketBeat
Pharvaris (NASDAQ:PHVS) Stock Price Up 5.2% - MarketBeat
Pharvaris (NASDAQ:PHVS) Trading Down 2.4% - MarketBeat
(PHVS) Trading Advice - Stock Traders Daily
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
Pharvaris (NASDAQ:PHVS) Shares Up 5.1% - MarketBeat
Price T Rowe Associates Inc. MD Sells 84,783 Shares of Pharvaris (NASDAQ:PHVS) - Defense World
(PHVS) Investment Analysis and Advice - Stock Traders Daily
Viridian, Pharvaris said to be among prime M&A targets for Biogen - Seeking Alpha
Contrasting Avidity Biosciences (NASDAQ:RNA) and Pharvaris (NASDAQ:PHVS) - American Banking and Market News
Contrasting Avidity Biosciences (NASDAQ:RNA) and Pharvaris (NASDAQ:PHVS) - Defense World
Pharvaris (NASDAQ:PHVS) Price Target Raised to $38.00 at Oppenheimer - Defense World
Financial Analysis: Pharvaris (NASDAQ:PHVS) versus AC Immune (NASDAQ:ACIU) - Defense World
When the Price of (PHVS) Talks, People Listen - Stock Traders Daily
Pharvaris Announces Changes to its Board of Directors - Quantisnow
Pharvaris Shareholders Approve Key Resolutions - TipRanks
Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms with 44% ownership, institutions own 26% - Yahoo New Zealand News
(PHVS) Investment Analysis - Stock Traders Daily
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):